Susceptibility of Mice to Trypanosoma evansi Treated with Human Plasma Containing Different Concentrations of Apolipoprotein L-1.
10.3347/kjp.2011.49.4.427
- Author:
Aleksandro S DA SILVA
1
;
Vinicius R FANFA
;
Mateus A OTTO
;
Lucas T GRESSLER
;
Kaio CS TAVARES
;
Cicera R LAZZAROTTO
;
Alexandre A TONIN
;
Luiz C MILETTI
;
Marta MMF DUARTE
;
Silvia G MONTEIRO
Author Information
1. Department of Microbiology and Parasitology, Universidade Federal de Santa Maria, Brazil. aleksandro_ss@yahoo.com.br
- Publication Type:Brief Communication
- Keywords:
Trypanosoma evansi;
mouse;
treatment;
human plasma;
apolipoprotein-1
- MeSH:
Adult;
Animals;
Apolipoproteins/blood/*therapeutic use;
DNA, Protozoan/genetics;
Female;
Humans;
Lipoproteins, HDL/blood/*therapeutic use;
Male;
Mice;
Polymerase Chain Reaction;
Trypanocidal Agents/blood/*therapeutic use;
Trypanosoma/drug effects/genetics/*pathogenicity;
Trypanosomiasis/drug therapy/mortality/*parasitology;
Young Adult
- From:The Korean Journal of Parasitology
2011;49(4):427-430
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups (A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plasma 2 (D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of 40.9+/-0.3 (C), 20+/-9.0 (D) and 35.6+/-9.3 (E) days compared to the control group (B) which was 4.3+/-0.5 days. The number of surviving mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treatments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl of APOL1, respectively. However, we believe that this difference in the treatment efficiency is related to the level of APOL1 in plasmas.
